Effectiveness of different models of maintenance therapy for bronchial asthma (BA) in routine clinical practice Source: Eur Respir J 2007; 30: Suppl. 51, 70s Year: 2007
A comparison of clinical characteristics between cough variant asthma (CVA) and bronchial asthma (BA) in adult patients Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010
Influence of basic therapy of bronchial asthma (BA) on respiratory symptoms in patients with pulmonary TB associated with bronchial asthma Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Budesonid/formoterol easyhaler: clinical efficiency and adherence to treatment in patients with partly controlled bronchial asthma (BA). Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Achievement of asthma control in patients with cold airway hyperresponsiveness at different variants of basic therapy Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment? Year: 2013
Salmeterol, added to usual therapy, is an effective bronchodilator over 12 months of treatment in chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
Influence of combined antiasthmatic basic therapy on hyperinflation in patients with severe bronchial asthma Source: Eur Respir J 2007; 30: Suppl. 51, 553s Year: 2007
High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Does lung function change in the months after an asthma exacerbation in children? Source: Virtual Congress 2021 – Paediatric asthma and bronchopulmonary dysplasia Year: 2021
Pharmacogenetic control of bronchial obstruction in steroid depend asthma (SDBA) patients Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011
Pharmacogenetic markers of steroid dependent bronchial asthma (BA) control Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Influence of modern basic therapy of bronchial asthma (BA) on the course of pulmonary TB in patients with pulmonary TB associated with asthma Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011